Drug Profile
GSK 706769
Alternative Names: CCR5 inhibitor (GSK706769) - GSK; GSK706769Latest Information Update: 01 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiretrovirals
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in USA (PO, Tablet)
- 31 May 2008 GlaxoSmithKline initiates a second phase I trial of GSK 706769 in healthy volunteers in USA
- 20 Sep 2005 Preclinical trials in HIV-1 infections in USA (unspecified route)